Ginkgo Bioworks Acquires Proof Diagnostics

Original from: FinSMEs

Ginkgo Bioworks (NYSE: DNA), a Boston, MA-based company which is building a platform for cell programming and biosecurity, announced the acquisition of Proof Diagnostics, a life sciences tools, diagnostics and computational discovery company.

​

The amount of the deal was not disclosed.

With the acquisition, Ginkgo Bioworks will expand its offerings.

Proof was founded by Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Drs. Omar Abudayyeh and Jonathan Gootenberg of the McGovern Institute for Brain Research at MIT, and Sid Shenai to develop a low cost, rapid, easy-to-use, and sensitive diagnostic system – for SARS-CoV-2, Flu A/B, RSV and other diseases, including oncology – using CRISPR-based and other technologies.

Led by Jason Kelly, CEO, Ginkgo Bioworks provides a horizontal platform for cell programming, offering flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats.

​

Source: Ginkgo Bioworks Acquires Proof Diagnostics